International S. Pharmstandard Buys 43,618 Shares of Argos Therapeutics Inc. (ARGS) Stock
Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard purchased 43,618 shares of the firm’s stock in a transaction on Thursday, September 29th. The stock was acquired at an average cost of $4.56 per share, for a total transaction of $198,898.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) opened at 4.97 on Friday. The stock’s market capitalization is $204.74 million. The company’s 50 day moving average price is $4.78 and its 200 day moving average price is $5.93. Argos Therapeutics Inc. has a one year low of $1.61 and a one year high of $13.97.
Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. On average, equities analysts expect that Argos Therapeutics Inc. will post ($1.56) earnings per share for the current year.
ARGS has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Argos Therapeutics in a research note on Friday, June 17th. Zacks Investment Research raised Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Monday, August 15th. FBR & Co reduced their price objective on Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Thursday, August 11th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Argos Therapeutics in a research note on Monday, June 20th. Eight analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $11.50.
A number of hedge funds have recently modified their holdings of ARGS. Geode Capital Management LLC increased its stake in shares of Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 3,559 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Argos Therapeutics by 184.5% in the second quarter. Bank of New York Mellon Corp now owns 52,215 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 33,862 shares during the last quarter. California State Teachers Retirement System acquired a new stake in shares of Argos Therapeutics during the second quarter valued at approximately $137,000. Oxford Asset Management acquired a new stake in shares of Argos Therapeutics during the second quarter valued at approximately $353,000. Finally, Vanguard Group Inc. increased its stake in shares of Argos Therapeutics by 57.2% in the second quarter. Vanguard Group Inc. now owns 377,497 shares of the biopharmaceutical company’s stock valued at $2,314,000 after buying an additional 137,390 shares during the last quarter. 11.05% of the stock is currently owned by institutional investors and hedge funds.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.